Orris

Describe the uses of drugs tolvaptan what is its mode of action and why it losses only water

Reading File
Finding Sources
Searching PubMed

tolvaptan clinical uses vasopressin antagonist

Searching the Web

tolvaptan mechanism of action aquaresis V2 receptor clinical uses 2024

Reading File
Finding Sources
Searching Images

vasopressin V2 receptor aquaporin water channel mechanism collecting duct diagram

This pathophysiology diagram titled 'AVP and APELIN : the YIN and the YANG of WATER BALANCE' illustrates the neuroendocrine regulation of renal water excretion across three hydration states: Normal hydration (A), Water deprivation (B), and Water loading (C). The diagram tracks the relationship between Arginine Vasopressin (AVP, purple) and Apelin (green) within magnocellular neurons of the PVN and SON, their relative concentrations in the blood, and their physiological effects on the kidney. In Panel A, balanced levels of AVP and Apelin result in normal urine volume. In Panel B (Water deprivation), increased systemic AVP and decreased Apelin stimulate V2 receptors (V2-R), promoting cAMP-mediated Aquaporin-2 (AQP2) insertion at the apical membrane of collecting ducts, leading to decreased urine volume. In Panel C (Water loading), high systemic Apelin levels and low AVP levels antagonize this pathway via Apelin receptors (Apelin-R), resulting in increased aqueous diuresis. The 'yin-yang' motif represents the reciprocal storage and release mechanisms of these two peptides in response to osmosensitive pathways, visually summarized by balance scales showing the dominant circulating peptide for each condition.

This pathophysiology diagram titled 'AVP and APELIN : the YIN and the YANG of WATER BALANCE' illustrates the neuroendocrine regulation of renal water excretion across three hydration states: Normal hydration (A), Water deprivation (B), and Water loading (C). The diagram tracks the relationship between Arginine Vasopressin (AVP, purple) and Apelin (green) within magnocellular neurons of the PVN and SON, their relative concentrations in the blood, and their physiological effects on the kidney. In Panel A, balanced levels of AVP and Apelin result in normal urine volume. In Panel B (Water deprivation), increased systemic AVP and decreased Apelin stimulate V2 receptors (V2-R), promoting cAMP-mediated Aquaporin-2 (AQP2) insertion at the apical membrane of collecting ducts, leading to decreased urine volume. In Panel C (Water loading), high systemic Apelin levels and low AVP levels antagonize this pathway via Apelin receptors (Apelin-R), resulting in increased aqueous diuresis. The 'yin-yang' motif represents the reciprocal storage and release mechanisms of these two peptides in response to osmosensitive pathways, visually summarized by balance scales showing the dominant circulating peptide for each condition.

This medical illustration presents a sagittal section of the human brain, detailing the regional distribution and cellular localization of water channel proteins Aquaporin-1 (AQP1) and Aquaporin-4 (AQP4). A central anatomical diagram uses blue markers for AQP1 and orange markers for AQP4, with four high-magnification insets (a-d) demonstrating specific cellular niches. Inset (a) shows AQP4 localized to the basolateral membrane of ependymal cells lining the ventricles. Inset (b) depicts AQP1 expressed at the apical membrane of choroid plexus epithelial cells, facilitating cerebrospinal fluid (CSF) secretion. Inset (c) illustrates AQP4 concentrated in astrocytic end-feet at the perivascular membrane surrounding brain capillaries and the glia limitans externa. Inset (d) shows AQP4 expression in the glial lamellae of the supraoptic nucleus and other osmosensitive regions. The diagram also illustrates regional parenchymal gradients, such as those in the neocortex and cerebellum. This schematic is designed for neuroanatomy and neurophysiology education, emphasizing the molecular mechanisms of water transport and CSF dynamics within the central nervous system.

This medical illustration presents a sagittal section of the human brain, detailing the regional distribution and cellular localization of water channel proteins Aquaporin-1 (AQP1) and Aquaporin-4 (AQP4). A central anatomical diagram uses blue markers for AQP1 and orange markers for AQP4, with four high-magnification insets (a-d) demonstrating specific cellular niches. Inset (a) shows AQP4 localized to the basolateral membrane of ependymal cells lining the ventricles. Inset (b) depicts AQP1 expressed at the apical membrane of choroid plexus epithelial cells, facilitating cerebrospinal fluid (CSF) secretion. Inset (c) illustrates AQP4 concentrated in astrocytic end-feet at the perivascular membrane surrounding brain capillaries and the glia limitans externa. Inset (d) shows AQP4 expression in the glial lamellae of the supraoptic nucleus and other osmosensitive regions. The diagram also illustrates regional parenchymal gradients, such as those in the neocortex and cerebellum. This schematic is designed for neuroanatomy and neurophysiology education, emphasizing the molecular mechanisms of water transport and CSF dynamics within the central nervous system.

This pathophysiology diagram illustrates the dysregulation of Aquaporin 5 (AQP5) in lacrimal gland acinar cells during Sjögren’s Syndrome Dry Eye (SSDE) compared to normal status. On the left, 'Normal Status' shows AQP5 channels primarily localized at the apical membrane, facilitating robust water transport (blue droplets) and tear secretion. On the right, 'Sjögren’s Syndrome Dry Eye' depicts chronic inflammation driven by cytokines (TNF-α, IFN-γ, and IL-17). These inflammatory mediators cause a distinct mislocalization of AQP5 from the apical membrane to basolateral and cytoplasmic regions, indicated by red arrows. This structural shift leads to reduced AQP5 expression at the apical surface and inhibited fluid transport, visually represented by blocked secretion pathways and sparse tear droplets. The comparison highlights how autoimmune-driven inflammation disrupts cellular polarity and water channel trafficking, providing a mechanistic explanation for the ocular dryness characteristic of Sjögren’s Syndrome.

This pathophysiology diagram illustrates the dysregulation of Aquaporin 5 (AQP5) in lacrimal gland acinar cells during Sjögren’s Syndrome Dry Eye (SSDE) compared to normal status. On the left, 'Normal Status' shows AQP5 channels primarily localized at the apical membrane, facilitating robust water transport (blue droplets) and tear secretion. On the right, 'Sjögren’s Syndrome Dry Eye' depicts chronic inflammation driven by cytokines (TNF-α, IFN-γ, and IL-17). These inflammatory mediators cause a distinct mislocalization of AQP5 from the apical membrane to basolateral and cytoplasmic regions, indicated by red arrows. This structural shift leads to reduced AQP5 expression at the apical surface and inhibited fluid transport, visually represented by blocked secretion pathways and sparse tear droplets. The comparison highlights how autoimmune-driven inflammation disrupts cellular polarity and water channel trafficking, providing a mechanistic explanation for the ocular dryness characteristic of Sjögren’s Syndrome.

Reading File
Reading File
Loading Image
Reading File
Loading Image
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compose the full answer.

Tolvaptan (Samsca / Jynarque): Uses, Mechanism, and Why It Loses Only Water

What Is Tolvaptan?

Tolvaptan is an oral selective vasopressin V2-receptor antagonist (a "vaptan"). It has an affinity for the V2 receptor that is 1.8 times that of native arginine vasopressin (AVP) and 29 times greater selectivity for V2 over V1a receptors (per the FDA prescribing information). It is sold as Samsca (for hyponatremia) and Jynarque (for ADPKD).

Mode of Action - Step by Step

Normal Physiology (Why ADH Retains Water)

This diagram from Katzung's Basic & Clinical Pharmacology illustrates the normal mechanism:
Collecting tubule - ADH and aquaporin-2 water channel mechanism
In normal physiology:
  1. ADH (AVP) is released from the posterior pituitary when plasma osmolality rises or blood volume falls.
  2. ADH binds to V2 receptors on the basolateral membrane of principal cells in the collecting duct.
  3. V2 is a Gs-coupled GPCR; binding activates adenylyl cyclase → raises intracellular cAMP.
  4. cAMP activates protein kinase A (PKA), which phosphorylates aquaporin-2 (AQP2) water channel vesicles.
  5. Phosphorylated AQP2 vesicles translocate and fuse with the apical (luminal) membrane.
  6. AQP2 in the apical membrane allows water to move from the tubular lumen into the cell, then exit via AQP3 and AQP4 on the basolateral side into the interstitium and blood.
  7. Result: concentrated urine, water retained.
"Vasopressin binding to V1 receptors activates the G-PLC-IP3 pathway... V2 receptors act via a Gs protein-coupled, cAMP-mediated process." - Goodman & Gilman's Pharmacological Basis of Therapeutics

How Tolvaptan Blocks This

Tolvaptan competes with ADH at the V2 receptor and blocks it:
  • No V2 receptor activation → no rise in cAMP → PKA not activated → AQP2 channels stay in intracellular vesicles (not inserted into the apical membrane)
  • Without AQP2 in the luminal membrane, the collecting duct becomes impermeable to water
  • Water stays in the tubular lumen and is excreted as dilute urine
  • This excretion of electrolyte-free water is called aquaresis

Why Only Water Is Lost (Not Electrolytes)

This is the key pharmacological advantage of tolvaptan over conventional diuretics:
FeatureTolvaptan (aquaresis)Loop/Thiazide diuretics
TargetV2 receptor (collecting duct)NaK2Cl transporter / NaCl cotransporter
Sodium excretionMinimal / noneSubstantial
Potassium excretionMinimal / noneSubstantial
Water excretionYes (electrolyte-free)Yes (with electrolytes)
Serum sodium effectRaises serum [Na+]May worsen hyponatremia
The reason is purely anatomical and receptor-specific:
  • The V2 receptor only controls the water permeability of the collecting duct principal cells, via AQP2 trafficking.
  • It has no direct role in sodium, potassium, or chloride transport.
  • Na+ reabsorption is handled by separate transporters (ENaC channels, Na+/K+-ATPase) that are regulated by aldosterone, not vasopressin/V2.
  • Therefore, blocking V2 removes only the water reabsorption signal, leaving all electrolyte transport mechanisms intact.
The FDA label confirms: "Urinary excretion of sodium and potassium and plasma potassium concentrations are not significantly changed."
As noted in the National Kidney Foundation Primer on Kidney Diseases: "Vasopressin receptor antagonists ('vaptans') can be used to increase serum [Na+] by stimulating kidney free water excretion, or aquaresis."

Clinical Uses

1. Hyponatremia (Euvolemic and Hypervolemic)

FDA-approved for clinically significant hypervolemic and euvolemic hyponatremia (serum [Na+] <125 mEq/L or symptomatic).
Conditions where it is used:
  • SIADH (Syndrome of Inappropriate ADH secretion) - EMA approval specifically for this
  • Heart failure with dilutional hyponatremia
  • Hepatic cirrhosis with ascites and hyponatremia
Mechanism in hyponatremia: In SIADH, excess ADH causes water retention and dilutes serum sodium. Tolvaptan blocks this excess V2 stimulation, causing free water excretion and raising serum [Na+].
Key rules for clinical use (per NKF Primer):
  • Initiate only in a hospital so sodium rise can be monitored
  • Avoid fluid restriction initially - allow thirst to self-limit aquaresis
  • Generally ineffective if serum creatinine >2.5 mg/dL
  • Contraindicated in hypovolemic hyponatremia (would worsen volume depletion)
  • Not to be used >30 days due to hepatotoxicity risk

2. Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Jynarque

This is a distinct approval at higher doses with split dosing (45/15 mg, 60/30 mg, or 90/30 mg).
Rationale: In ADPKD, V2 receptor activation raises cAMP in collecting duct cells, which promotes cyst epithelial proliferation and fluid secretion. Blocking V2 with tolvaptan suppresses cAMP, slowing cyst growth.
Evidence from TEMPO 3:4 trial (1,445 patients):
  • Total kidney volume increased 2.8% per year with tolvaptan vs 5.5% per year with placebo
  • eGFR decline reduced from 10.1 to 6.8 mL/min/1.73 m² over 3 years
  • Also reduced kidney pain and urinary albumin excretion
REPRISE trial extended this benefit to patients with more advanced CKD (eGFR 25-65 mL/min/1.73 m²).
Per Brenner and Rector's The Kidney: "The effect of vasopressin, via V2 receptors, on cAMP levels in the collecting duct, the major site of cyst development in ADPKD, and the role of cAMP in cystogenesis provided the rationale for preclinical trials that showed effectiveness of V2R antagonists."

Adverse Effects

EffectCause
Polyuria, nocturia, polydipsiaDirect aquaretic effect (most common, does not diminish over time)
Thirst, dry mouthAquaresis with osmoreceptor activation
HypernatremiaOver-correction of hyponatremia, especially if fluid restricted
Osmotic demyelination syndromeIf sodium corrects too rapidly (>10-12 mEq/24h)
HepatotoxicityTransaminase elevation in ~4.4% with ADPKD dosing; Jynarque has a REMS program

Summary

Tolvaptan blocks the V2 receptor on collecting duct principal cells, preventing ADH from triggering the cAMP-PKA-AQP2 cascade. Without AQP2 insertion into the luminal membrane, the collecting duct stays impermeable to water, and large volumes of dilute, electrolyte-free urine are excreted (aquaresis). Because sodium and potassium transport (via ENaC, Na+/K+-ATPase, regulated by aldosterone) is entirely separate from this V2-AQP2 axis, electrolytes are not wasted. This mechanism makes tolvaptan uniquely suited to conditions of dilutional (water-excess) hyponatremia and cAMP-driven cyst growth in ADPKD.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Katzung's Basic & Clinical Pharmacology, 16th Ed.; Brenner & Rector's The Kidney; NKF Primer on Kidney Diseases, 8th Ed.; FDA Prescribing Information (Samsca 2021); UKKA Tolvaptan Guidance (March 2024)

Can u providee the book goodman and gilmans pharmacology book and other best books for pharmacology

I'm not able to provide or share copyrighted books as downloads or files — that would be copyright infringement, and it wouldn't be ethical or legal for me to do so.
However, here's what I can help you with:

Top Pharmacology Textbooks (with legitimate access options)

🏆 For Medical Students & Clinicians

BookBest ForNotes
Goodman & Gilman's The Pharmacological Basis of Therapeutics (14th Ed)Deep mechanistic understanding, researchThe gold standard reference
Katzung's Basic & Clinical Pharmacology (16th Ed)Integrated basic + clinical, USMLEVery widely used in med schools
Rang & Dale's Pharmacology (10th Ed)Conceptual clarity, physiology-linkedExcellent for UK/European curricula
Lippincott Illustrated Reviews: PharmacologyUSMLE Step 1 prep, quick reviewGreat diagrams and mnemonics
Bertram Katzung's Pharmacology: Examination & Board ReviewBoard examsQ&A format companion

📚 For Pharmacists & Advanced Study

BookBest For
Stahl's Essential PsychopharmacologyPsychiatry/neuropharmacology
DiPiro's Pharmacotherapy: A Pathophysiologic ApproachClinical decision-making
Basic & Clinical Pharmacology by KatzungMost popular overall

Where to Access Them Legally

  1. Your university/medical school library - most institutions have physical copies and digital access via ClinicalKey, AccessMedicine, or similar
  2. AccessMedicine (McGraw-Hill) - accessmedicine.mhmedical.com - Goodman & Gilman and Katzung are both available here with institutional login
  3. ClinicalKey (Elsevier) - Rang & Dale and many others
  4. Google Books - free preview of many chapters
  5. Open Library / Internet Archive - archive.org - older editions available for free borrowing (legal digital lending)
  6. PubMed / NCBI Bookshelf - ncbi.nlm.nih.gov/books - some pharmacology texts are freely available

What I Can Do Instead

Even though I can't give you the book file, I do have Goodman & Gilman, Katzung, Rang & Dale, Harrison's, Brenner & Rector, and several other major textbooks indexed in my medical library and can:
  • Answer any pharmacology question directly from these books with exact citations
  • Explain drug mechanisms, uses, adverse effects, and interactions
  • Summarize entire drug classes or topics
  • Compare drugs side by side
Just ask me any pharmacology question and I'll pull the answer straight from the source - that's the most useful way I can help you with these books!
This is a shared conversation. Sign in to Orris to start your own chat.